Natera NTRA stock
Natera, Inc. · Healthcare · end-of-day data as of Nov 13, 2026
- Price target at$393.16 +23.2%
- ConsensusBuy · 23
- Trendbullish
- Sector▲ +15.9%
- Earnings in104d
- RSI34
- Support-2.8%
- Resistance+0.7%
- Off 52w high-27.1%
- Volume0.8x
- Bollingerlower half
- News0.00
- FCF yield+0.1%
- 52w range$181–$437
- ATR+6.8%
- Off ATH-27.1%
- Insiders-$104M
- MAs1 of 4
- MA20×50Death 0d ago
- MACD-9.77
Updates with the 15-min delayed price; analysts, insiders and news are from the last close. Not a forecast or investment advice.
What changed
- Last close (Nov 13): NTRA -1.2% = market (SPY) -0.4% + Healthcare sector +0.7% + NTRA on its own -1.5%.
- Last 5 sessions to Nov 13: NTRA +2.7% = market (SPY) +2.6% + Healthcare sector -1.8% + NTRA on its own +1.9%.
Analyst price targets and predictions
16 firms with a target in the last 12 months · last close $319.09 · as of Nov 13, 2026
Strong buy 4Buy 17Hold 2Sell 0Strong sell 0
23 analysts in November 2026: 21 rate it a buy or strong buy (91%) and 2 a hold. A year earlier, 89% rated it a buy or strong buy.
Is Natera a good stock to buy?
Natera is strong on 2 of the 5 questions about the business; weak on economics and execution. With a loss over the last 12 months, Natera has no P/E ratio (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand growing
- Advantage some edge
- Economics losing money
- Execution misses
- Fragility sturdy
- Price like its peers
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.
Snapshot
- P/E—
- P/E vs sector—
- P/E vs own—
- Price target at+23.2%
- ConsensusBuy
- Market cap$46.27B
- FCF yield+0.1%
- Insiders-$104M
- Earnings in104d
- News0.00
Why it moved
0 stories on the day (30-day average 1.4).
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $319.09 · +59.0% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendbullish
- Sector▲ +15.9%
- MAs20▼ 50▼ 100▼ 200▲
- Above MAs1 of 4 above
- MA20×50Death 0d ago
- RSI34
- Support-2.8%
- Resistance+0.7%
- Off 52w high-27.1%
- Off ATH-27.1%
- 52w range$319.09
- Bollingerlower half
- MACD-9.77
- ATR+6.8%
- Volume0.8x
Revenue and free cash flow
Q3 FY2026: Revenue +34.1% year over year, free cash flow 0.7% of revenue, operating margin -8.6%.
| Q3 FY2026 | Sep 30, 2026 | $794M | -0.42 | $5.25M | 64.8% | -8.6% | -7.5% |
| Q2 FY2026 | Jun 30, 2026 | $753M | -0.47 | -$8.64M | 64.5% | -10.1% | -8.9% |
| Q1 FY2026 | Mar 31, 2026 | $697M | -0.60 | $18.03M | 64.8% | -13.4% | -12.2% |
| Q4 FY2025 | Dec 31, 2025 | $666M | 0.35 | $37.82M | 67.1% | -3.4% | 7.1% |
| Q3 FY2025 | Sep 30, 2025 | $592M | -0.64 | $24.48M | 64.9% | -16.5% | -14.8% |
| Q2 FY2025 | Jun 30, 2025 | $547M | -0.74 | $11.68M | 63.5% | -20.2% | -18.5% |
| Q1 FY2025 | Mar 31, 2025 | $502M | -0.50 | $22.64M | 63.2% | -15.8% | -13.3% |
| Q4 FY2024 | Dec 31, 2024 | $476M | -0.41 | $34.77M | 62.9% | -13.6% | -11.3% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $704.23 | +0.9% | -8.5% | +5.3% | 47.8 | $55.48B | |
| 2 |  | $173.96 | +0.5% | -4.9% | +0.2% | 34.2 | $49.05B | |
| 3 | | $319.09 | -1.2% | -27.1% | +23.2% | — | $46.27B | |
| 4 |  | $460.25 | -0.4% | -4.8% | +0.3% | 197.5 | $45.24B | |
| 5 |  | $265.12 | -2.2% | -6.8% | +6.8% | 32.2 | $43.69B | |
| 6 |  | $1,738.91 | +0.5% | -3.7% | -11.9% | 37.7 | $34.59B | |
| 7 |  | $207.01 | -1.2% | -33.1% | +11.2% | 35.6 | $31.3B | |
| 8 |  | $370.48 | -0.5% | -1.2% | +0.8% | 30.4 | $30.08B |
Data as of Nov 13, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.